Taxus chinensis Fruit Extract Suppresses Neuroinflammation v

2026-06-07

Taxus chinensis Fruit Extract Suppresses Neuroinflammation via TLR4 Inhibition

Study Background and Research Question

Taxus chinensis (Pilg.) Rehder fruit, used traditionally in Chinese folk medicine, has been reputed for its potential to boost immune function and support healthy aging. Despite anecdotal evidence and preliminary biochemical analyses suggesting anti-oxidative and anti-inflammatory properties, rigorous mechanistic studies addressing its neuroprotective effects and underlying molecular pathways have been lacking. The reference study (Chen et al., 2025) directly tackles this gap by exploring whether Taxus chinensis fruit extract (TCFE) can attenuate neuroinflammation and aging behaviors, with a focus on the TLR4/NF-κB/NLRP3 inflammatory pathway in a D-galactose-induced aging mouse model.

Key Innovation from the Reference Study

A central advance of this study is the systematic demonstration that TCFE exerts robust anti-aging and anti-neuroinflammatory effects via selective inhibition of microglial TLR4 signaling. Mechanistically, the study identifies that key bioactive constituents of TCFE—most notably procyanidin B2 and rutin—bind strongly to TLR4, providing a molecular explanation for the extract’s efficacy. This direct modulation of the TLR4/NF-κB/NLRP3 axis in the hypothalamus links traditional herbal use to a modern immunological target, bridging ethnopharmacology and molecular neuroscience. The work also uniquely benchmarks TCFE’s cellular effects against a classic small molecule TLR4 inhibitor (C34), enhancing translational relevance for inflammatory signaling research.

Methods and Experimental Design Insights

The investigators established an aging phenotype in mice using chronic D-galactose administration, a well-characterized model for mimicking oxidative stress and neuroinflammation seen in aging. Mice received low, medium, or high doses of TCFE, with a positive control group treated with rapamycin plus metformin. Behavioral outcomes were assessed alongside biochemical analyses of serum oxidative markers (MDA, SOD, TAOC), inflammatory cytokines (IL-1β, IL-6, IFN-γ, TNFα, IL-17, IL-10), and hypothalamic markers of cellular senescence (β-galactosidase activity, P63 expression). At the tissue level, microglial activation and the activation status of TLR4, NF-κB, and NLRP3 were evaluated using immunohistochemistry and Western blotting. In vitro, LPS-stimulated BV2 microglial cells were used to dissect the direct anti-inflammatory effect of TCFE, with C34—a selective small molecule TLR4 inhibitor—used as a reference comparator. UPLC-MS/MS profiling and molecular docking studies identified and characterized the bioactive components mediating TLR4 inhibition.

Protocol Parameters

D-galactose aging induction: Subcutaneous injection; dose and duration per reference protocols for robust aging phenotype.
TCFE dosing: Low, medium, and high doses calibrated by body weight; administered daily via oral gavage.
Positive control: Rapamycin (2 mg/kg) and metformin (100 mg/kg) administered as standard anti-aging comparators.
In vitro microglia assay: BV2 cells pre-treated with TCFE or C34 followed by LPS stimulation; cytokine and pathway marker quantification by ELISA and Western blotting.
UPLC-MS/MS component analysis: Bioactive compound identification using authentic standards and molecular docking with TLR4 for interaction profiling.

Core Findings and Why They Matter

TCFE treatment led to significant improvements in behavioral deficits associated with aging, along with reductions in serum MDA and pro-inflammatory cytokines. Antioxidant markers (SOD, TAOC) and anti-inflammatory cytokine IL-10 increased, while hypothalamic senescence and p63 levels decreased, indicating enhanced cellular integrity. Importantly, TCFE robustly inhibited microglial activation and suppressed TLR4, NF-κB, and NLRP3 expression in hypothalamic tissues, with the high-dose group outperforming the rapamycin/metformin control. In vitro, TCFE reduced IL-1β, TLR4, and NF-κB levels in LPS-stimulated BV2 microglia, with efficacy comparable to C34—a selective TLR4 inhibitor widely used in inflammatory pathway research. The study’s molecular docking and UPLC-MS/MS results pinpointed procyanidin B2 and rutin as the principal TLR4-binding constituents, supporting a direct mechanism for TLR4 pathway suppression. These findings are highly relevant for researchers investigating the role of microglial TLR4 signaling in neuroinflammation and aging, and they provide a translational rationale for both botanical and synthetic approaches to TLR4 modulation.

Comparison with Existing Internal Articles

The mechanistic conclusions of this study align closely with prior internal syntheses, such as Taxus chinensis Fruit Suppresses Neuroinflammation via TLR4 Inhibition, which summarizes the attenuation of neuroinflammation and aging behaviors by TCFE through microglial TLR4 pathway inhibition. Notably, the reference study’s direct comparison of TCFE to the small molecule TLR4 inhibitor C34 adds a critical translational link, highlighted in internal reviews such as C34 TLR4 Inhibitor: Selective Suppression in Inflammatory Pathways. The parallel efficacy observed between TCFE and C34 in both in vitro and in vivo models underscores the value of small molecule TLR4 inhibitors in dissecting inflammatory signaling mechanisms, particularly in macrophages and microglia. Furthermore, internal resources such as C34 TLR4 Inhibitor: Enhancing Inflammatory Pathway Research emphasize the role of C34 in necrotizing enterocolitis research, suggesting broader applicability of TLR4 inhibition strategies across systemic and neurological inflammatory models.

Limitations and Transferability

While the study robustly demonstrates the anti-neuroinflammatory and anti-aging effects of TCFE in a D-galactose-induced mouse model, several limitations warrant consideration. The precise pharmacokinetics and bioavailability of the major TLR4-inhibiting constituents in vivo remain to be fully elucidated. The D-galactose model, though widely used, does not capture the full complexity of human aging or neurodegenerative conditions. Additionally, while the molecular docking data suggest strong TLR4 binding, direct structural or biophysical validation of these interactions in primary human microglia would strengthen translational confidence. The comparison to C34 is compelling, yet further studies in human tissue or disease-relevant models are needed to confirm equivalency and practical workflow integration.

Research Support Resources

For researchers aiming to dissect TLR4-mediated inflammatory pathways in macrophages, enterocytes, or microglia, validated chemical tools are essential. C34 (CAS 40592-88-9) TLR4 Inhibitor (SKU B4925) is a small molecule shown to selectively suppress TLR4-dependent signaling at ~10 μM in vitro and at 1 mg/kg in vivo, according to product information and related research. It is particularly suited for workflows modeling inflammatory responses in macrophages and enterocytes, as well as studies in necrotizing enterocolitis and neuroinflammation. Researchers can reference APExBIO for high-purity C34 and detailed protocol guidance. The parallels between botanical inhibitors like those in TCFE and synthetic modulators such as C34 provide a robust foundation for advancing inflammatory signaling research using both natural and chemical tools.